Blog Entry: January 26th, 2010
2 Sateren, W. B., et al. (2002). How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. Journal of Clinical Oncology, 20, 2109-2117.
Christian, M. C., & Trimble, E. L. (2003). Increasing participation of physicians and patients from
underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials. Cancer Epidemiology Biomarkers & Prevention, 12, 277s-283s.; Cancer clinical trials: A resource guide for outreach, education, and advocacy. Retrieved 2006 from National Cancer Institute Web site: www.cancer.gov/clinicaltrials/resources/outreach-education-advocacy; Digest Page: Boosting Cancer Trial Participation. Retrieved 2006 from National Institutes of Health, National Cancer Institute Web site: http://cancer.gov/clinicaltrials/digestpage/boosting-trial-participation
3 Brawley, O. The study of accrual to clinical trials: Can we learn from studying who enters our studies? Journal of Clinical Oncology, 2004. 22(11), 2039-2040.
4 Murthy VH, Krumholz HM, Gross CP Participation in cancer clinical trials: race-, sex-, and age-based disparities.; JAMA. 2004 Jun 9;291(22):2720-6.
Stewart et al Participation in Surgical Oncology Clinical Trials:Gender-, Race/Ethnicity-, and Age-based Disparities Annals of Surgical Oncology 14(12):3328-3334
5 Dilts, D. (2008). (Vanderbilt University) Personal correspondence based on unpublished data of CALGB and ECOG; February 2, 2008.